City Therapeutics Prices IPO at $18 Per Share, Raising $200 Million

3-line summary

• City Therapeutics (ticker: CTY), a clinical-stage biotech developing RNA-interference therapies, priced its IPO at $18 per share for 11,111,111 shares, raising about $200 million before fees; the offering is entirely newly issued shares, with underwriters granted a 30-day option to purchase up to 1,666,666 additional shares. The stock lists on the Nasdaq Global Market, with the SEC registration statement effective October 15, trading starting October 16, and closing expected October 19.
• Underwriters include Goldman Sachs & Co. LLC, Jefferies, Stifel, and Oppenheimer & Co. Key pipeline programs cited: CITY-FXI for thromboembolic disorders, CITY-RBP4 for Stargardt disease and other retinal disorders, and CITY-TFR2 for anemia related to chronic disease.
• The article did not specify planned use of proceeds.

This summary is our own processing of the source article; see the source link below for full context.